

To Business Editor  
[For immediate release]

**Lee's Pharmaceutical Holdings Limited**  
**李氏大藥廠控股有限公司**

**Lee's Pharmaceutical Establishes New R&D Centre at the Hong Kong Science Park  
To Bolster the Group's R&D Capabilities**

[17 December 2008 – Hong Kong] **Lee's Pharmaceutical Holdings Limited** ("**Lee's Pharmaceutical**" or the "Group", Stock Code: 8221) is an integrated, research-driven and market-oriented pharmaceuticals group in China. Today they announced the establishment of a new research and development centre at the Hong Kong Science Park to further enhance the Group's overall R&D capabilities. This facility, together with the Group's existing mainland R&D centre in Hefei City, Anhui province, will help strengthen the core competitiveness while also satisfying customer demand during the current global economic turmoil.

**Lee's Pharmaceutical** is aiming to expand during the current economic slowdown through this R&D Centre at Phase 2 of the Science Park. The facility comprises a gross floor area of 1,724 square feet and represents an investment of HK\$5 million. As part of the Group's on-going expansion plans, activities at the Science Park will mainly focus on peptide drug research and development. The laboratory will be established and run according to Good Laboratory Practice (GLP) guidelines. Pre-clinical studies such as chemistry and manufacturing development, specification development, formulation screening and stability study will be carried out at the site.

The expansion of the Group's R&D centre from Hefei, Anhui to Hong Kong Science Park will allow the Group to tap into the rich resources of Hong Kong as an international business centre, strengthening the R&D capacity and capability of the Group and improving its competitiveness in the drug development area. The new site will be erected in February 2009 and the team will be staffed with members from Hefei and from local recruitment of up to 5 persons. According to the Groups' third quarter results, significant clinical study progress was achieved following the completion of both the Bemiparin and *Horus®S* Stent study projects. Moreover, the Group's PLC and ALC clinical studies have begun patient enrollment and are progressing well. Clinical studies for *Veloderm®*, which are applied during skin grafts, have been initiated, bringing the total number of ongoing clinical studies to four. Moreover, three additional clinical studies entered into the planning and preparation phase during the third quarter.

According to **Dr. Benjamin Li, CEO** of the Group - "The establishment of this research and development centre at the Hong Kong Science Park will benefit us greatly with modern, large-scale lab facilities, which will, in turn, strengthen the Group's overall R&D capabilities. Innovation is the driving force for sustained growth. Against the backdrop of current "financial tsunami", investment in research and development is the only future for business. Going forward we will continue to invest in drug development and relentlessly pursue excellence in quality. By augmenting the pipelines and bringing innovative products into the market, we can effectively expand the Group's revenue base."

**Information about Lee's Pharmaceutical Holdings Limited**

**Lee's Pharmaceutical Holdings Limited**, a biopharmaceutical company operating in China for over 14 years, was successfully listed on the Growth Enterprise Market (GEM) of the Stock Exchange of Hong Kong Limited in 2002. It is a fully integrated biopharmaceutical company with a solid infrastructure in both drug and clinical development. In addition, it carries out regulatory matters as well as manufacturing, sales and marketing activities throughout China. Lee's currently markets six products in China. Their drugs focus on various clinical areas, including cardiovascular and infectious diseases, dermatology, oncology, gynecology and others with more than 15 products currently at different development stages. This is the result of both internal R&D activities as well as from their recent acquisition of licensing and distribution rights from various US and European corporations.

*~ end ~*

Issued by Porda International (Finance) PR Company Limited for and on behalf of **Lee's Pharmaceutical Holdings Limited**. For further information, please contact:

Porda International (Finance) PR Company Limited

Ms. Keely Chan	keely@pordafinance.com.hk	Tel: (852) 3150 6760 / (852) 9770 2950
Ms. Alman Loong	alman@pordafinance.com.hk	Tel: (852) 3150 6731 / (852) 9107 8225
Ms. Phoebe Sou	phoebe@pordafinance.com.hk	Tel: (852) 3150-6736 / (852) 9174 1743
Ms. Liz Yip	liz@pordafinance.com.hk	Tel: (852) 3150-6739 / (852) 9497 1685
Fax: (852) 3150-6728		